Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES. Corporate presentation Aktiespararna Södertälje, April 18 th 2016 Anna Ljung, CFO

Transcription

1 Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Corporate presentation Aktiespararna Södertälje, April 18 th 2016 Anna Ljung, CFO 0

2 Disclaimer Statements included herein that are not historical facts are forward-looking statements. Such forwardlooking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Moberg Pharma s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Moberg Pharma s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Moberg Pharma s interim or annual reports, prospectuses or press releases. 1 1

3 Moberg Pharma PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Net Sales grew to 286 MSEK (full year 2015) - U.S. OTC Sales operations - Products sold in 40+ countries - 35 employees in Sthlm and NJ Focus in OTC/Dermatology/Topicals - Leading U.S. OTC SKU in Nail Fungus - Superior PII data for MOB015 Market Cap ~750 MSEK (OMX:MOB) 2 2

4 Moberg Pharma PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Outlook Profitable growth, targeting a long-term EBITDA margin of at least 25% Strategic elements Growth strategy - Organic growth - M&A/Innovation engine Build value through combining Brand/IP Equity 3 3

5 2015 Continued growth and doubling of profit

6 Highlights from Q415 and Q116 to date Q415 net sales grew by 7% to MSEK 54 Year-on-year, 2015 net sales grew by 43% (21% at fixed exchange rates) and EBITDA improved by 83% Asian launch driving growth in distributor sales Innovation engine progress Bupi Ph II results, Colep, Cadila, reg meetings SEK 300 million raised in the Nordic bond market to finance growth and acquisitions Divestment of three non-core brands enable increased focus on strategic assets 5 5

7 Growth in 2015 improved EBITDA with 83% m m Net Sales, MSEK 286 (+43%) EBITDA, MSEK EBITDA Commercial Operations, MSEK % 16% 22% 24% 68 (+58%) 46 (+83%) NOTE: EBITDA Commercial Operations does not include R&D and Business Development expenses for future products outside existing brands 6

8 23 consecutive quarters of Sales growth Product Sales, TTM, MSEK Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q

9 P&L - Sales growth and doubling of profit P&L Summary (MSEK) Q Q FY 2015 FY 2014 Revenue Gross profit % 68% 72% 75% 75% SG & A R&D existing product portfolio 1) Other operating income/operating expenses EBITDA Commercial Operations % 16% 21% 24% 22% R&D & BD future products 2) EBITDA % 8% 8% 16% 13% Depreciation/amortization Operating profit (EBIT) ) Research and development expenses existing product portfolio includes R&D expenses for new product variants under existing brands, regulatory work and quality. 2) Research and development expenses - future products includes R&D expenses for new product candidates, for example MOB Due to the rounding component, totals may not tally. 8

10 Majority of revenue from direct OTC sales Launches in Asia drives RoW product sales Distribution of revenue, January December 2015 Sales via distributors 28% JointFlex 13% Kerasal 11% Other 21% RoW 15% Europe 11% Direct OTC Sales 72% Nalox/ Kerasal Nail 55% Americas 74% Channels Products Geography 9 9

11 Solid cash position and positive cash flow Full-year 2015 Full-year 2014 Operative cash flow +31 MSEK +16 MSEK Cash position 45 MSEK 62 MSEK Not including: Bond issue of 300 MSEK closed in January 2016 Bond structure also allows tap issues of additional 300 MSEK Divestment of three non-core brands for 10 MUSD closed in April

12 Progress in Commercial Operations

13 Focus on strategic brands Strategic brands Kerasal - Foot care Emtrix Balmex - Diaper rash Domeboro - Derma/Skin irritation Mature brands Divested April 1, 2016 Jointflex - External analgesic Vanquish - Internal analgesic Fergon - Iron supplement 12 12

14 Kerasal Nail - the OTC market leader in the U.S. No 1 with 22% market share in Q ) Key claim visible difference in 2 weeks. Product supported by 4 clinical studies Available at > points of sale 13 1) Retail sales of nail fungus products excluding private label in Multioutlet Stores over the last 52 weeks ending December 27, 2015 as reported by SymphonyIRI 13

15 Scalable infrastructure for marketing U.S OTC brands Contract Manufacturers Sales Force Retailers/ Wholesalers Sales and marketing/brand Management Logistics Note: Largest retailers and wholesalers only, not an all inclusive list.

16 Closed Balmex acquisition April 24, 2015 Acquired from Chattem (Sanofi) for $3.9 million (MSEK 33.3) Sales trending above $4 million annually Deal financed with existing funds Strong heritage in baby diaper rash with broad distribution in major chains: 15 15

17 Distributor Sales well positioned for further growth Sales in >40 markets Growth in Europe (+7%) - Emtrix rights in six EU markets taken back Asian launches progresses well and rapid growth of sales - 6 markets launched - Ongoing preparations in other Large growth potential Note: Four largest distributors only, not an all inclusive list.bv 16 16

18 Launches in Asia a key growth driver Malaysia Launch Q4 2014, already market leader Hong Kong Excellent start of sales and reorders Singapore Launch started, to be ramped up China Regional launch started in May 2015 Indonesia Launch and TV started Aug 2015 Philippines Launch started Nov Other markets Launch preparations ongoing 17

19 Innovation Engine

20 Pipeline assets - Building on Topical drug delivery know how Pipeline asset Indication Status MOB-015 Onychomycosis Ph III preparation BUPI Oral Mucositis and oral pain Ph III preparation Peak sales potential, m$ USP Topical terbinafine with fast visible improvement and superior cure rates Lozenge formulation with effective pain relief for 2-3 hrs(vs 0,5 hrs for competition) 19 19

21 MOB-015 USPs and Strategy USPs Targets a superior profile, in mild to moderate onychomycosis based on phase II data and experience from the OTC product (>600 patients in clinical trials and >10 million units sold to date): 1 Superior cure rates Mycological and Clinical 2 Shorter treatment time potentially 6 months 3 First visible improvement within 2-4 weeks Strategy Prepare Phase III to start in 2016 Objective to maintain control of asset in key territories through phase III 20 20

22 BUPI targets to provide additional and prolonged pain relief Product & Indication BUPI (bupivacaine lozenge) for oral pain relief (mouth and throat) 1 st indication: Oral Mucositis in cancer patients. Large unmet need Other indications: Burning Mouth Syndrome, Sjögren s syndrome, Upper gastrointestinal endoscopy. Long-term also OTC potential. Value and Next steps Peak Sales potential $50-100m, whereof the OM indication is $20-25m Positive topline Phase II data 21 21

23 Innovation Engine 4 ACQUISITIONS LAST 40 MONTHS 4 PATENTS APPROVED 2015 Organic growth Current products growing, adding new markets Line extensions adding incremental growth - Focus on strategic brands 5 patent families enable additional products - MOB-015, K-Nail+ patents granted Acquisitions/inlicensing Brands - Focus on US OTC market Pipeline assets enabling new products Completed Acquisitions Alterna LLC, Nov 2012, $26m (2.3x Sales) Bayer brands, Dec 2013, $4.8m (1.6x Sales) Bupizenge, April 2014, dev. project,$1m Balmex, April 2015, $3.9m (<1x Net Sales) 22 22

24 Focus next 12 months PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Intends to make significant investments in Strengthening strategic brands in U.S. - Broadening international distribution, - Acquiring additional products/assets - Initiating phase III studies for MOB-015 U.S: Execution of Kerasal brand strategy Asia key growth driver, additional launches Long-term target Create shareholder value through profitable growth targeting a long-term EBITDA margin of at least 25% 23 23

25 Why invest in Moberg Pharma Commercial niche strategy enables a growing and profitable base business Pipeline with large potential and at reasonable risk - Proven molecules limit development risk, cost and TTM Acquisition strategy with substantial value potential - 4 acquisitions in last 40 months - Team, systems and infrastructure in place to enable scale-up - Capacity to finance deals Strong Team with track record 24 24

26 Q&A 25 25